Cardax Inc.’s revenue plunged 47.3% in the first quarter as the health store chain selling its anti-inflammatory product ZanthoSyn worked through existing inventory and ramped up promotions. Read more
Mahalo for reading the Honolulu Star-Advertiser!
You're reading a premium story. Read the full story with our Print & Digital Subscription.Subscribe Now